KZR's Business Model
Kezar Life Sciences, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer in the United States. The company's lead product candidate is KZR-616, a selective immunoproteasome inhibitor that is in Phase 2 clinical trials for various indications, including lupus nephritis, dermatomyositis, and polymyositis; and Phase 1b clinical trials in systemic lupus erythematosus and lupus nephritis. Its preclinical products include KZR-261, a novel first-in-class protein secretion inhibitor for the treatment of KZR-261; and KZR-TBD for the treatment of oncology and immunology. The company was incorporated in 2015 and is based in South San Francisco, California.
| Sector & Industry | Healthcare / Biotechnology |
| Website | https://www.kezarlifesciences.com |
| CEO (Chief Executive Officer) | Christopher J. Kirk |
| Number of Employees | |
| IPO date | June 21, 2018 |
KZR Latest News
|
|
|
|
|
|
|
|
|
|
| Contact | |
|---|---|
| Country | US |
| Address | 4000 Shoreline Court |
| City | South San Francisco |
| State | CA |
| Phone | 650 822 5600 |
| Zip Code | 94080 |
| Other Identifiers | |
| CIK | 0001645666 |
| ISIN | US49372L2097 |
| CUSIP | 49372L100 |
| Open | 7.25 |
| Previous Close | 7.18 |
| Volume | 11.01 Thou. |
| Average Volume | 39.18 Thou. |
| Day’s Range | 6.82 – 7.25 |
| 52 Week Range | 3.53-7.45 |
| MA (50) | 6.4554 |
| MA (200) | 5.26515 |
| Market Cap | 50.16 Mil. |
| Shares Out. | 7.32 Mil. |
| Earnings Date | Mar 31, 2026 |
| Beta | |
| Last Dividend | |
| EPS | |
| PE | |
